The effect of carnitine for intermittent claudication of peripheral arterial disease patient with sarcopenia and carnitine deficiency
Not Applicable
- Conditions
- Peripheral arterial disease(PAD), Arteriosclerosis obliterans(ASO)
- Registration Number
- JPRN-UMIN000016267
- Lead Sponsor
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Acute limb ischemia 2) Preferred revascularization for symptoms 3) Comorbidity taking precedence of treatment 4) Bleeding disorders 5) Congestive heart failure 6) Drug allergy of cilostazole or carnitine 7) Pregnant female 8) The patient judged inappropriate by the doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pretreatment of carnitine: cross-sectional areas of skeletal muscle at the thigh and lumbar part, serum carnitine level, absolute claudication distance, symptom, ABI Post treatment of carnitine: serum carnitine level, absolute claudication distance, symptom, cross-sectional areas of skeletal muscle at the thigh and lumbar part at 6 months after carnitine treatment
- Secondary Outcome Measures
Name Time Method Adverse event, serum carnitine level, absolute claudication distance, symptom at 4 weeks and 3 months after carnitine treatment